208 related articles for article (PubMed ID: 33194674)
1. Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models.
Yeh CC; Liao PY; Pandey S; Yung SY; Lai HC; Jeng LB; Chang WC; Ma WL
Front Oncol; 2020; 10():572861. PubMed ID: 33194674
[TBL] [Abstract][Full Text] [Related]
2. Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.
Tai Y; Zhang LH; Gao JH; Zhao C; Tong H; Ye C; Huang ZY; Liu R; Tang CW
Cancer Manag Res; 2019; 11():2831-2848. PubMed ID: 31114336
[No Abstract] [Full Text] [Related]
3. Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
Chu TH; Chan HH; Hu TH; Wang EM; Ma YL; Huang SC; Wu JC; Chang YC; Weng WT; Wen ZH; Wu DC; Chen YA; Tai MH
Cancer Med; 2018 Jun; 7(6):2567-2580. PubMed ID: 29683262
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway.
Zhang C; Zhou J; Hu J; Lei S; Yuan M; Chen L; Wang G; Qiu Z
RSC Adv; 2019 Jul; 9(36):20624-20632. PubMed ID: 35515542
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Zuo C; Qiu X; Liu N; Yang D; Xia M; Liu J; Wang X; Zhu H; Xie H; Dan H; Li Q; Wu Q; Burns M; Liu C
Exp Cell Res; 2015 May; 333(2):316-326. PubMed ID: 25724899
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1.
Dai H; Zhang S; Ma R; Pan L
Med Sci Monit; 2019 Sep; 25():7351-7360. PubMed ID: 31568401
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
[TBL] [Abstract][Full Text] [Related]
9. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
10. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
11. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.
Torimura T; Iwamoto H; Nakamura T; Koga H; Ueno T; Kerbel RS; Sata M
Transl Oncol; 2013; 6(5):511-9. PubMed ID: 24151531
[TBL] [Abstract][Full Text] [Related]
13. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Cui W; Hu SX; Tang ZY; Hu KQ
Anticancer Drugs; 2008 Oct; 19(9):891-7. PubMed ID: 18766003
[TBL] [Abstract][Full Text] [Related]
14. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
15. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
16. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
Sareddy GR; Geeviman K; Ramulu C; Babu PP
J Neurooncol; 2012 Jan; 106(1):99-109. PubMed ID: 21847707
[TBL] [Abstract][Full Text] [Related]
17. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Iwamoto H; Torimura T; Nakamura T; Hashimoto O; Inoue K; Kurogi J; Niizeki T; Kuwahara R; Abe M; Koga H; Yano H; Kerbel RS; Ueno T; Sata M
Neoplasia; 2011 Mar; 13(3):187-97. PubMed ID: 21390182
[TBL] [Abstract][Full Text] [Related]
18. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
Cervello M; Bachvarov D; Cusimano A; Sardina F; Azzolina A; Lampiasi N; Giannitrapani L; McCubrey JA; Montalto G
OMICS; 2011 Jun; 15(6):383-92. PubMed ID: 21410330
[TBL] [Abstract][Full Text] [Related]
19. Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway.
Srivastava S; Dewangan J; Mishra S; Divakar A; Chaturvedi S; Wahajuddin M; Kumar S; Rath SK
Phytomedicine; 2021 Apr; 84():153484. PubMed ID: 33667839
[TBL] [Abstract][Full Text] [Related]
20. Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma.
Hu JW; Chen B; Zhang J; Qi YP; Liang JH; Zhong JH; Xiang BD
J Cancer; 2020; 11(21):6437-6444. PubMed ID: 33033527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
